We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial

MedXY Editorial Team•Mar 2, 2026•Gastroenterology
neoadjuvant therapyPancreatic Cancer

Highlights of the CASSANDRA Trial

The PACT-21 CASSANDRA trial represents a significant milestone in the management of pancreatic ductal adenocarcinoma (PDAC). The primary highlights of the first randomization analysis include:

1. Survival Advantage: Preoperative PAXG demonstrated a statistically significant improvement in median event-free survival (EFS) compared to mFOLFIRINOX (16.0 months vs. 10.2 months), representing a 37% reduction in the risk of progression or death.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Real-World Five-Year Survival After Neoadjuvant Therapy and Surgery in Localized Pancreatic Ductal AdenocarcinomaThis study reveals that over one-third of patients with localized PDAC receiving neoadjuvant therapy and surgery achieve actual five-year survival, highlighting the impact of early systemic failure and identifying factors predicting long-teSep 15, 2026Unveiling Hidden High-Risk Phenotypes in Resected Solid Pseudopapillary Tumors Using Anomaly-Detection ModelsThis study employs interpretable anomaly-detection algorithms to identify high-risk phenotypes in resected solid pseudopapillary pancreatic tumors, overcoming limitations of conventional survival models in ultra-rare cancer-specific deaths.Sep 15, 2026Balancing Efficacy and Safety: Neoadjuvant Immunochemoradiotherapy vs. Immunochemotherapy in Elderly Esophageal Squamous Cell CarcinomaIn elderly patients with locally advanced esophageal squamous cell carcinoma, neoadjuvant immunochemoradiotherapy offers superior tumor response but increases surgical complexity and cardiac risks compared to immunochemotherapy. PersonalizeSep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Circulating Exosomal microRNA Signature Enhances Preoperative Detection of Occult Liver Metastases in Pancreatic Cancer
A multicenter study developed a robust exosomal microRNA-based model enabling preoperative detection of occult liver micrometastasis in pancreatic ductal adenocarcinoma, improving risk stratification and guiding treatment sequencing.
Sep 7, 2026
Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial ReviewThis review synthesizes evidence from a phase 3 trial demonstrating improved pathological complete response rates with neoadjuvant anbenitamab and HB1801 in ERBB2-positive breast cancer, highlighting efficacy, safety, and clinical implicatiSep 6, 2026
Targeting the CA19-9 Glycan: A Promising CAR T Cell Therapy for Pancreatic and Gastrointestinal CancersCAR T cells targeting the CA19-9 glycan show potent, specific anti-tumor activity in pancreatic and various gastrointestinal cancers, providing new avenues for immunotherapy of hard-to-treat solid tumors.Aug 29, 2026